Swiss exchange wants to entice biotech companies
This article was originally published in Clinica
Executive Summary
The Swiss stock exchange wants biotechnology companies to launch their IPOs on its market. The "New Market" in Zurich notes that US diagnostics and device flotations have not attracted the same numbers of subscribers that have flocked to Internet share offerings and argues that biotech IPO's in Switzerland could draw on the fact that Switzerland has traditionally been home to pharmaceutical companies.